DCA Officials Seize ‘Diclojan Forte’ Tab For Misleading Claims

HYDERABAD: Officials of Drugs Control Administration, Telangana seized ‘DICLOJAN Forte Tablets (Diclofenac Sodium & Paracetamol Tablets),’ in Aiza Village, Jogulamba-Gadwal District, for making a misleading advertisement claiming it treats ‘fever.

In a statement here on Thursday, DCA Director-General VB Kamalasan Reddy said that the officials detected a medicine ‘DICLOJAN Forte Tablets’ circulating in the market with misleading claim on its label that it treats ‘fever’, which is a contravention of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. During the special raids conducted on 24th, and 25th April, officials from the Drugs Control Administration, Mahabubnagar Zone, detected ‘DICLOJAN Forte Tablets’. The said medicine was detected by DCA officials at a medical shop situated in Aiza Village, Aiza Mandal, Jogulamba-Gadwal District. Stocks were seized during the raid.

The advertisement of a medicine for the treatment of ‘fever’ in general is prohibited under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Mohd. Rafhi Shaik, Drugs Inspector, Gadwal and A.N. Kranthi Kumar, Drugs Inspector, Narayanpet are among the officers who carried out the raid. Further investigation shall be carried out and action shall be taken as per the law against all the offenders.

Persons who make misleading advertisements regarding drugs for treatment of certain diseases and disorders are punishable under Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, with imprisonment which may extend to six months, or with fine, or with both.

The public may report any complaints regarding illegal activities concerning medicines through the Drugs Control Administration, Telangana Toll-Free Number 1800-599-6969, which is operational from 10:30 am to 5:00 pm on all working days.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre